InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.069 0.003 (4.55%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$37 Notice Under Section 708A 11 Feb 2022 5:14PM $0.315 $0.069 fallen by 78.10%
$37 Application for quotation of securities - IMU 11 Feb 2022 4:50PM $0.315 $0.069 fallen by 78.10%
$37 Change of Director's Interest Notice - JE 9 Feb 2022 10:58AM $0.310 $0.069 fallen by 77.74%
$37 Notification regarding unquoted securities - IMU 7 Feb 2022 8:17AM $0.310 $0.069 fallen by 77.74%
$37 Notice Under Section 708A 4 Feb 2022 6:07PM $0.310 $0.069 fallen by 77.74%
$37 Application for quotation of securities - IMU 4 Feb 2022 5:47PM $0.310 $0.069 fallen by 77.74%
$37 Application for quotation of securities - IMU 4 Feb 2022 5:25PM $0.310 $0.069 fallen by 77.74%
$37 BPAY or EFT Process for IMUOC & IMUOD Option Holders 4 Feb 2022 5:01PM $0.310 $0.069 fallen by 77.74%
$37 Notification regarding unquoted securities - IMU 1 Feb 2022 6:28PM $0.330 $0.069 fallen by 79.09%
$37 Appointment of Dr Steven Cha as Chief Medical Officer 1 Feb 2022 8:21AM $0.310 $0.069 fallen by 77.74%
$37 Issue of Options under the Employee Share Option Plan 31 Jan 2022 6:45PM $0.310 $0.069 fallen by 77.74%
$37 Oncolytic Virotherapy CF33 Patent Granted in Japan 31 Jan 2022 9:52AM $0.315 $0.069 fallen by 78.10%
$37 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jan 2022 5:13PM $0.315 $0.069 fallen by 78.10%
$37 PD1-Vaxx Clinical Trial Supply Agreement with Roche 28 Jan 2022 12:07PM $0.293 $0.069 fallen by 76.41%
$37 HER-Vaxx Immunotherapy Patent Granted in Europe 28 Jan 2022 9:05AM $0.285 $0.069 fallen by 75.79%
$37 Application for quotation of securities - IMU 21 Jan 2022 5:36PM $0.335 $0.069 fallen by 79.40%
$37 Retirement of Chief Medical Officer 21 Jan 2022 10:20AM $0.358 $0.069 fallen by 80.70%
$37 Application for quotation of securities - IMU 14 Jan 2022 5:15PM $0.350 $0.069 fallen by 80.29%
$37 Release of Securities from Escrow 10 Jan 2022 5:11PM $0.360 $0.069 fallen by 80.83%
$37 Imugene Receives $6.54 million R&D Tax Incentive 6 Jan 2022 7:37PM $0.360 $0.069 fallen by 80.83%
$37 South Korea HERVaxx Patent Grant 6 Jan 2022 10:22AM $0.380 $0.069 fallen by 81.84%
$37 Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx 4 Jan 2022 9:30AM $0.400 $0.069 fallen by 82.75%
$37 Imugene adds industry leaders to senior management team 4 Jan 2022 9:27AM $0.400 $0.069 fallen by 82.75%
$37 Notice Under Section 708A 23 Dec 2021 5:14PM $0.410 $0.069 fallen by 83.17%
$37 Notification regarding unquoted securities - IMU 23 Dec 2021 5:11PM $0.410 $0.069 fallen by 83.17%

476 - 500 of 1199 results

Page 20 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.